These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 21818086)

  • 1. A suPAR circulating factor causes kidney disease.
    Shankland SJ; Pollak MR
    Nat Med; 2011 Aug; 17(8):926-7. PubMed ID: 21818086
    [No Abstract]   [Full Text] [Related]  

  • 2. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.
    Wei C; El Hindi S; Li J; Fornoni A; Goes N; Sageshima J; Maiguel D; Karumanchi SA; Yap HK; Saleem M; Zhang Q; Nikolic B; Chaudhuri A; Daftarian P; Salido E; Torres A; Salifu M; Sarwal MM; Schaefer F; Morath C; Schwenger V; Zeier M; Gupta V; Roth D; Rastaldi MP; Burke G; Ruiz P; Reiser J
    Nat Med; 2011 Jul; 17(8):952-60. PubMed ID: 21804539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.
    Staeck O; Slowinski T; Lieker I; Wu K; Rudolph B; Schmidt D; Brakemeier S; Neumayer HH; Wei C; Reiser J; Budde K; Halleck F; Khadzhynov D
    Transplantation; 2015 Dec; 99(12):2593-7. PubMed ID: 26371597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification.
    Morath C; Wei C; Macher-Goeppinger S; Schwenger V; Zeier M; Reiser J
    Am J Ther; 2013; 20(2):226-9. PubMed ID: 23466622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum suPAR in patients with FSGS: trash or treasure?
    Maas RJ; Deegens JK; Wetzels JF
    Pediatr Nephrol; 2013 Jul; 28(7):1041-8. PubMed ID: 23515666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab.
    Alachkar N; Li J; Matar D; Vujjini V; Alasfar S; Tracy M; Reiser J; Wei C
    BMC Nephrol; 2018 Dec; 19(1):361. PubMed ID: 30558559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focal Segmental Glomerulosclerosis Recurrence: Soluble Urokinase Receptor Left Out?
    Canaud G; Loupy A
    Transplantation; 2015 Dec; 99(12):2449-50. PubMed ID: 26371599
    [No Abstract]   [Full Text] [Related]  

  • 8. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.
    Huang J; Liu G; Zhang YM; Cui Z; Wang F; Liu XJ; Chu R; Zhao MH
    BMC Med; 2014 May; 12():81. PubMed ID: 24884842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. suPAR and chronic kidney disease-a podocyte story.
    Zeier M; Reiser J
    Pflugers Arch; 2017 Aug; 469(7-8):1017-1020. PubMed ID: 28689240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View.
    Kronbichler A; Saleem MA; Meijers B; Shin JI
    J Immunol Res; 2016; 2016():2068691. PubMed ID: 27504461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A circulating factor responsible for FSGS? suPAR!].
    Esposito V
    G Ital Nefrol; 2012; 29(1):7. PubMed ID: 22388895
    [No Abstract]   [Full Text] [Related]  

  • 12. Soluble urokinase receptor and focal segmental glomerulosclerosis.
    Reiser J; Wei C; Tumlin J
    Curr Opin Nephrol Hypertens; 2012 Jul; 21(4):428-32. PubMed ID: 22569341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.
    Alfano M; Cinque P; Giusti G; Proietti S; Nebuloni M; Danese S; D'Alessio S; Genua M; Portale F; Lo Porto M; Singhal PC; Rastaldi MP; Saleem MA; Mavilio D; Mikulak J
    Sci Rep; 2015 Sep; 5():13647. PubMed ID: 26380915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.
    Harel E; Shoji J; Abraham V; Miller L; Laszik Z; Thurison T; King A; Olshen A; Leung J; Szabo G; Hann B; Høyer-Hansen G; Craik CS; Vincenti F
    Clin Transplant; 2019 Mar; 33(3):e13487. PubMed ID: 30689221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating factor in FSGS: a black sheep in the suPAR family?
    Trachtman H; Wei C; Reiser J
    Pediatr Nephrol; 2013 Jul; 28(7):1151-2. PubMed ID: 23572245
    [No Abstract]   [Full Text] [Related]  

  • 16. Has the circulating permeability factor in primary FSGS been found?
    Jefferson JA; Shankland SJ
    Kidney Int; 2013 Aug; 84(2):235-8. PubMed ID: 23903418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAGE and αVβ3-integrin are essential for suPAR signaling in podocytes.
    Kim EY; Dryer SE
    Biochim Biophys Acta Mol Basis Dis; 2021 Oct; 1867(10):166186. PubMed ID: 34166766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein A immunoadsorption cannot significantly remove the soluble receptor of urokinase from sera of patients with recurrent focal segmental glomerulosclerosis.
    Beaudreuil S; Zhang X; Kriaa F; Dantal J; Francois H; Vazquez A; Charpentier B; Lorenzo HK; Durrbach A
    Nephrol Dial Transplant; 2014 Feb; 29(2):458-63. PubMed ID: 24235085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria.
    Zhang B; Xie S; Shi W; Yang Y
    Nephrol Dial Transplant; 2012 May; 27(5):1746-55. PubMed ID: 22076430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. suPAR and focal segmental glomerulosclerosis.
    Praga M
    Nefrologia; 2014; 34(2):145-8. PubMed ID: 24658189
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.